Epredia

Epredia provides comprehensive anatomical pathology solutions to global laboratories, encompassing histology instruments, consumables, and advanced digital pathology systems. Offerings include whole slide imaging, image analysis software, immunohistochemistry, and cytology products. These technologies optimize pre-analytical workflows, enhancing diagnostic precision and efficiency for accurate disease detection.

Epredia was established in July 2019 by PHC Holdings Corporation, acquiring Thermo Fisher Scientific's anatomical pathology business. This strategic move created a global entity focused on precision cancer diagnostics. The formation leveraged deep pathology heritage, fostering concentrated innovation within this specialized market.

Anatomical pathology laboratories worldwide rely on Epredia’s products for critical diagnostic workflows, especially cancer detection. The company equips pathologists and professionals with advanced tools for sample preparation, imaging, and analysis. Epredia’s vision is to improve patient outcomes by advancing diagnostic precision and accessibility for more informed treatment decisions.